Technical Analysis for EPZM - Epizyme, Inc.

Grade Last Price % Change Price Change
F 9.78 1.98% 0.19
EPZM closed up 1.98 percent on Monday, March 1, 2021, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical EPZM trend table...

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 1.98%
Spinning Top Other 1.98%
Lower Bollinger Band Walk Weakness 1.98%
New 52 Week Low Weakness 1.98%
Below Lower BB Weakness 1.98%
Older End-of-Day Signals for EPZM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% about 7 hours ago
60 Minute Opening Range Breakdown about 7 hours ago
Rose Above Lower Bollinger Band about 11 hours ago
Up 2% about 11 hours ago
Up 1% about 11 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Epizyme, Inc. Description

Epizyme, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, planning, and commercialization of various personalized therapeutics for the treatment of patients with genetically defined cancers. Its principal product candidates under development include EPZ-5676, an intravenously administered small molecule inhibitor of DOT1L that is in Phase I clinical trials for the treatment of mixed lineage rearranged leukemia (MLL-r); and EPZ-6438, an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients caused by an oncogenic point mutation in EZH2. The company has strategic collaboration and license agreements with Celgene Corporation and Celgene International Sàrl, as well as Glaxo Group Limited to discover, develop, and commercialize small molecule HMT inhibitors; and Eisai Co., Ltd. (Eisai) to license its EZH2 program. It also has a companion diagnostic collaboration with Abbott Molecular Inc. for the development of a companion diagnostic to identify patients with the MLL-r genetic alteration targeted by EPZ-5676; and with Roche Molecular Systems, Inc., as well as with Eisai for the development and commercialization of a companion diagnostic for use with EPZ-6438 product candidate. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Cancers Lymphoma Leukemia Companion Diagnostic Hodgkin Lymphoma Non Hodgkin Lymphoma Eisai Ezh2

Is EPZM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 23.61
52 Week Low 9.42
Average Volume 953,579
200-Day Moving Average 13.38
50-Day Moving Average 11.38
20-Day Moving Average 10.76
10-Day Moving Average 10.34
Average True Range 0.61
ADX 13.58
+DI 11.68
-DI 23.14
Chandelier Exit (Long, 3 ATRs ) 10.26
Chandelier Exit (Short, 3 ATRs ) 11.25
Upper Bollinger Band 11.93
Lower Bollinger Band 9.60
Percent B (%b) 0.08
BandWidth 21.64
MACD Line -0.46
MACD Signal Line -0.35
MACD Histogram -0.1127
Fundamentals Value
Market Cap 993.46 Million
Num Shares 102 Million
EPS -1.86
Price-to-Earnings (P/E) Ratio -5.25
Price-to-Sales 113.20
Price-to-Book 6.49
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.34
Resistance 3 (R3) 10.30 10.08 10.24
Resistance 2 (R2) 10.08 9.94 10.10 10.21
Resistance 1 (R1) 9.93 9.85 10.01 9.97 10.18
Pivot Point 9.71 9.71 9.75 9.73 9.71
Support 1 (S1) 9.56 9.57 9.64 9.60 9.38
Support 2 (S2) 9.34 9.48 9.36 9.35
Support 3 (S3) 9.19 9.34 9.32
Support 4 (S4) 9.23